MAPT and Alzheimer disease: Our major finding was that those patients with a more AD-like CSF profile (low Aβ 1–42 level, high total-Tau level) and smaller left hippocampi at baseline, declined faster and more profoundly so that a possible benefit of AChE-I was undetectable.